Patent ID: 7652045

Claim:
A method for treating a condition or disorder associated with modulation of peroxisome proliferator-activated receptor delta (PPARδ) transactivation activity, wherein the condition or disorder is selected from the group consisting of dyslipidemia, hyperglycemia, hyperlipidemia, hypercholesterolemia, hyperlipoproteinemia, obesity, syndrome X, atherosclerosis, hyperphagia, ischemic disease, Alzheimer's disease, osteoporosis, Basedow's disease, adrenal cortical dystrophy, and cancer, wherein cancer is a lung cancer, mammary cancer, colon cancer, ovary cancer, or cancer of great intestine; said method comprising administering to a patient in need thereof a compound of the formula (I): or a salt thereof, wherein: R 1 is phenyl or naphthyl, each of which can have substituents selected from the group consisting of C 1-8 alkyl, C 1-8 alkyl having halogen, C 1-8 alkoxy, C 1-8 alkoxy having halogen, C 2-8 alkenyl, C 2-8 alkynyl, halogen, C 2-7 acyl, benzoyl, hydroxyl, nitro, amino, phenyl and pyridyl; R 2 is C 2-8 alkyl; A is oxygen or sulfur; X is a C 1-8 alkylene chain which can have a C 1-8 alkyl substituent and which can contain a double bond; Y is C(═O), CH═CH, or C(═CH 2 ) each of R 3 , R 4 and R 5 is hydrogen, C 1-8 alkyl, C 1-8 alkyl having halogen, C 1-8 alkoxy, C 1-8 alkoxy having halogen, C 2-8 alkenyl, C 2-8 alkynyl, halogen, C 2-7 acyl, benzoyl, hydroxyl, nitro, amino, phenyl, or pyridyl; B is CH; Z is oxygen or sulfur; each of R 6 and R 7 is hydrogen or C 1-8 alkyl; R 8 is hydrogen or C 1-8 alkyl; and provided that at least one of R 3 , R 4 and R 5 is not hydrogen.